arimoclomol has been researched along with Amyotrophic Lateral Sclerosis in 15 studies
*Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94) [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, M; Greensmith, L; Hanna, M; Harley, J; Patani, R; Spicer, C; Taylor, JP | 1 |
| Durham, HD; Fernandez, M; Gentil, BJ; Hermann, A; Kuta, R; Larochelle, N; Minotti, S; Nalbantoglu, JN; Pal, A; St Louis, K; Tibshirani, M | 1 |
| Andersen, PM; Atassi, N; Benatar, M; Cudkowicz, M; David, W; Schoenfeld, D; Wuu, J | 1 |
| McDermott, CJ | 1 |
| Greensmith, L; Kalmar, B; Lu, CH | 1 |
| Liščić, RM | 1 |
| Andres, CR; Blasco, H; Corcia, P; Gordon, PH; Patin, F | 1 |
| Barber, JR; Brown, RH; Cudkowicz, ME; Grasso, D; Schoenfeld, D; Shefner, JM; Shui, A; Simpson, E; Wieland, S; Yu, H; Zhang, H | 1 |
| Cheetham, ME; Gray, A; Greensmith, L; Kalmar, B; Margulis, B; Novoselov, S | 1 |
| Barber, J; Cudkowicz, M; Lanka, V; Wieland, S | 1 |
| Phukan, J | 1 |
| Edet-Amana, E; Greensmith, L; Kalmar, B | 1 |
| Dick, J; Greensmith, L; Kalmar, B; Lu, CH; Malaspina, A; Petzold, A | 1 |
| Burnstock, G; Dick, JR; Greensmith, L; Kalmar, B; Kieran, D; Riddoch-Contreras, J | 1 |
| Benn, SC; Brown, RH | 1 |
6 review(s) available for arimoclomol and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Clinical trials in amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Clinical Trials as Topic; Edaravone; Humans; Hydroxylamines; Neuroprotective Agents; Research Design; Treatment Outcome | 2019 |
The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol.
Topics: Amyotrophic Lateral Sclerosis; Animals; Endoplasmic Reticulum Chaperone BiP; Enzyme Induction; Heat-Shock Proteins; Heat-Shock Response; Humans; Hydroxylamines; Models, Biological; Molecular Targeted Therapy; Neuroprotective Agents | 2014 |
Molecular basis of ALS and FTD: implications for translational studies.
Topics: Amyotrophic Lateral Sclerosis; DNA-Binding Proteins; Frontotemporal Dementia; Humans; Hydroxylamines; Mutation; Riluzole | 2015 |
Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection.
Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Clinical Trials as Topic; Frontotemporal Dementia; Humans; Hydroxylamines; Memantine; Neuroprotective Agents; Riluzole; Superoxide Dismutase; Vitamin B 12 | 2016 |
Arimoclomol: a potential therapy under development for ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Clinical Trials as Topic; Cytoprotection; Drug Approval; Drug Evaluation, Preclinical; Heat-Shock Proteins; Humans; Hydroxylamines | 2009 |
Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Chaperonins; Drugs, Investigational; Heat-Shock Proteins; Heat-Shock Response; Humans; Hydroxylamines; Nerve Degeneration; Neurons; Neuroprotective Agents; Stress, Physiological; Up-Regulation | 2010 |
2 trial(s) available for arimoclomol and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Female; Humans; Hydroxylamines; Male; Middle Aged; Neuroprotective Agents; Severity of Illness Index; Superoxide Dismutase-1; Survival Analysis; Treatment Outcome | 2018 |
Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis.
Topics: Aged; Amyotrophic Lateral Sclerosis; Blood-Brain Barrier; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxylamines; Male; Middle Aged | 2008 |
7 other study(ies) available for arimoclomol and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Amplifying the Heat Shock Response Ameliorates ALS and FTD Pathology in Mouse and Human Models.
Topics: Amyotrophic Lateral Sclerosis; Animals; Frontotemporal Dementia; Heat-Shock Response; Humans; Hydroxylamines; Mice; Mutation | 2023 |
Depending on the stress, histone deacetylase inhibitors act as heat shock protein co-inducers in motor neurons and potentiate arimoclomol, exerting neuroprotection through multiple mechanisms in ALS models.
Topics: Amyotrophic Lateral Sclerosis; Animals; Cells, Cultured; Heat-Shock Proteins; Heat-Shock Response; Histone Deacetylase Inhibitors; HSP70 Heat-Shock Proteins; Hydroxylamines; Mice; Motor Neurons; Spinal Cord; Transcriptional Activation; Up-Regulation | 2020 |
Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS.
Topics: Age Factors; Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Disease Progression; Female; HSP70 Heat-Shock Proteins; Humans; Hydroxylamines; Male; Mice; Mice, Transgenic; Motor Neurons; Muscle, Skeletal; Spinal Cord; Statistics, Nonparametric; Superoxide Dismutase; Survival Analysis; Ubiquitin | 2008 |
Treatment with a coinducer of the heat shock response delays muscle denervation in the SOD1-G93A mouse model of amyotrophic lateral sclerosis.
Topics: Acetylcholinesterase; Amyotrophic Lateral Sclerosis; Animals; Choline O-Acetyltransferase; Disease Models, Animal; Disease Progression; GPI-Linked Proteins; Heat-Shock Response; HSP70 Heat-Shock Proteins; Hydroxylamines; Longitudinal Studies; Mice; Mice, Transgenic; Motor Neurons; Muscle Fibers, Fast-Twitch; Muscle Fibers, Slow-Twitch; Muscle, Skeletal; Neuromuscular Junction; Succinate Dehydrogenase; Superoxide Dismutase | 2012 |
Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Biomarkers; Disease Models, Animal; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Hydroxylamines; Mice; Mice, Inbred C57BL; Mice, Transgenic; Muscles; Neurofilament Proteins; Phosphorylation; Spinal Cord; Superoxide Dismutase; Superoxide Dismutase-1; Treatment Outcome | 2012 |
Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Progression; Heat-Shock Proteins; Humans; Hydroxylamines; Mice; Mice, Transgenic; Motor Neurons; Mutation; Superoxide Dismutase | 2004 |
Putting the heat on ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Heat-Shock Response; Hydroxylamines; Life Expectancy; Mice; Superoxide Dismutase | 2004 |